PR Newswire Clinical TrialsOriginal article
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
Phase 3positiveSacituzumab TirumotecanPembrolizumabPositive
AI Analysis
Summary
Kelun-Biotech's Phase III trial (OptiTROP-Lung06) met its primary endpoint, demonstrating that sacituzumab tirumotecan combined with pembrolizumab showed superiority over standard immunotherapy plus chemotherapy as first-line treatment for PD-L1-negative non-squamous NSCLC.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
OptiTROP-Lung06 trial met primary endpoint, demonstrating superiority of sac-TMT plus pembrolizumab over standard immunotherapy plus chemotherapy
Importance:7/10
Sentiment:
0.80
Phase 3NSCLConcologyimmunotherapypositive trial data
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 14, 2026 11:30 PM